ReShape Lifesciences Inc. (NASDAQ:RSLS) Short Interest Down 33.1% in April

ReShape Lifesciences Inc. (NASDAQ:RSLS) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totalling 487,800 shares, a decline of 33.1% from the March 31st total of 729,300 shares. Based on an average daily volume of 520,900 shares, the short-interest ratio is presently 0.9 days. Currently, 2.3% of the shares of the stock are sold short.

ReShape Lifesciences Price Performance

Shares of ReShape Lifesciences stock traded down $0.01 on Friday, hitting $0.17. The company’s stock had a trading volume of 318,579 shares, compared to its average volume of 292,479. ReShape Lifesciences has a 1 year low of $0.14 and a 1 year high of $2.80. The firm has a fifty day moving average price of $0.17 and a 200-day moving average price of $0.22.

Hedge Funds Weigh In On ReShape Lifesciences

An institutional investor recently bought a new position in ReShape Lifesciences stock. Armistice Capital LLC purchased a new stake in ReShape Lifesciences Inc. (NASDAQ:RSLS) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 188,000 shares of the medical device company’s stock, valued at approximately $64,000. Armistice Capital LLC owned approximately 5.45% of ReShape Lifesciences as of its most recent SEC filing. Institutional investors own 22.06% of the company’s stock.

ReShape Lifesciences Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation.